, NURS 1150: NURSE PHARMACOLOGY I
EXAM 1 — COMPREHENSIVE EXAMINATION
70 Multiple-Choice Questions with Complete Clinical Rationales
Question 1: 1. Which pharmacokinetic process is primarily responsible for the termination or
alteration of drug action through enzymatic transformation in the liver?
A. Absorption
B. Distribution
C. Metabolism (Biotransformation)
D. Excretion
Question 2: 2. A drug with a high first-pass effect will experience which of the following when
administered orally compared to IV administration?
A. Increased systemic bioavailability
B. Significantly reduced systemic bioavailability
C. Prolonged half-life
D. Immediate peak plasma concentration
Question 3: 3. What term describes the time required for the concentration of a drug in the body to
decrease by 50%?
A. Onset of action
B. Peak effect
C. Half-life (t1/2)
D. Therapeutic index
Question 4: 4. Which of the following parameters is the best indicator of the margin of safety of a
drug?
A. Plasma half-life
B. Therapeutic Index (TI)
C. Bioavailability percentage
D. Protein-binding capacity
Question 5: 5. An agonist drug is best defined as a medication that:
A. Blocks receptor activation by endogenous ligands
B. Binds to a receptor and produces a biological response
C. Binds irreversibly to plasma proteins without receptor interaction
D. Accelerates renal excretion of active metabolites
, Question 6: 6. A patient receives a loading dose of a medication. What is the primary clinical rationale
for administering a loading dose?
A. To minimize adverse gastrointestinal side effects
B. To rapidly achieve therapeutic plasma drug concentrations
C. To bypass first-pass hepatic metabolism entirely
D. To extend the elimination half-life of the drug
Question 7: 7. Which patient population is at the highest risk for adverse drug reactions due to age-
related declines in glomerular filtration rate (GFR)?
A. Neonates and infants
B. School-age children
C. Adolescents
D. Older adults (geriatric patients)
Question 8: 8. Competitive antagonists differ from non-competitive antagonists because competitive
antagonists:
A. Bind irreversibly to receptor allosteric sites
B. Bind reversibly to the active site and can be overcome by increasing agonist concentration
C. Permanently destroy the target receptor
D. Produce maximal agonist response independently
Question 9: 9. Which organ is primarily responsible for the excretion of water-soluble drug
metabolites?
A. Livers
B. Kidneys
C. Lungs
D. Skin
Question 10: 10. When administering protein-bound drugs to a patient with severe hypoalbuminemia,
the nurse should monitor for:
A. Reduced therapeutic efficacy due to rapid excretion
B. Increased free (active) drug concentration and heightened toxicity risk
C. Immediate drug resistance
D. Prolonged hepatic enzyme induction
Question 11: 11. Activation of beta-1 adrenergic receptors in the heart results in which of the
following physiological responses?
A. Bradycardia and decreased contractility
B. Tachycardia and increased myocardial contractility
C. Coronary artery vasoconstriction
EXAM 1 — COMPREHENSIVE EXAMINATION
70 Multiple-Choice Questions with Complete Clinical Rationales
Question 1: 1. Which pharmacokinetic process is primarily responsible for the termination or
alteration of drug action through enzymatic transformation in the liver?
A. Absorption
B. Distribution
C. Metabolism (Biotransformation)
D. Excretion
Question 2: 2. A drug with a high first-pass effect will experience which of the following when
administered orally compared to IV administration?
A. Increased systemic bioavailability
B. Significantly reduced systemic bioavailability
C. Prolonged half-life
D. Immediate peak plasma concentration
Question 3: 3. What term describes the time required for the concentration of a drug in the body to
decrease by 50%?
A. Onset of action
B. Peak effect
C. Half-life (t1/2)
D. Therapeutic index
Question 4: 4. Which of the following parameters is the best indicator of the margin of safety of a
drug?
A. Plasma half-life
B. Therapeutic Index (TI)
C. Bioavailability percentage
D. Protein-binding capacity
Question 5: 5. An agonist drug is best defined as a medication that:
A. Blocks receptor activation by endogenous ligands
B. Binds to a receptor and produces a biological response
C. Binds irreversibly to plasma proteins without receptor interaction
D. Accelerates renal excretion of active metabolites
, Question 6: 6. A patient receives a loading dose of a medication. What is the primary clinical rationale
for administering a loading dose?
A. To minimize adverse gastrointestinal side effects
B. To rapidly achieve therapeutic plasma drug concentrations
C. To bypass first-pass hepatic metabolism entirely
D. To extend the elimination half-life of the drug
Question 7: 7. Which patient population is at the highest risk for adverse drug reactions due to age-
related declines in glomerular filtration rate (GFR)?
A. Neonates and infants
B. School-age children
C. Adolescents
D. Older adults (geriatric patients)
Question 8: 8. Competitive antagonists differ from non-competitive antagonists because competitive
antagonists:
A. Bind irreversibly to receptor allosteric sites
B. Bind reversibly to the active site and can be overcome by increasing agonist concentration
C. Permanently destroy the target receptor
D. Produce maximal agonist response independently
Question 9: 9. Which organ is primarily responsible for the excretion of water-soluble drug
metabolites?
A. Livers
B. Kidneys
C. Lungs
D. Skin
Question 10: 10. When administering protein-bound drugs to a patient with severe hypoalbuminemia,
the nurse should monitor for:
A. Reduced therapeutic efficacy due to rapid excretion
B. Increased free (active) drug concentration and heightened toxicity risk
C. Immediate drug resistance
D. Prolonged hepatic enzyme induction
Question 11: 11. Activation of beta-1 adrenergic receptors in the heart results in which of the
following physiological responses?
A. Bradycardia and decreased contractility
B. Tachycardia and increased myocardial contractility
C. Coronary artery vasoconstriction
